BioCentury
ARTICLE | Clinical News

AKCEA-APO(a)-LRx: Ph IIb started

April 27, 2017 9:06 PM UTC

Ionis’ Akcea Therapeutics Inc. subsidiary began a double-blind, placebo-controlled, North American Phase IIb trial to evaluate 5 dose levels of subcutaneous AKCEA-APO(a)-LRx in about 270 patients with hyperlipoproteinemia(a) and established cardiovascular disease...